hus14

Recommendations

Info

For More Information. See the NIS website at: http://www.cdc.gov/nchs/nis.htm. National Income and Product Accounts (NIPA) Bureau of Economic Analysis (BEA) Overview. NIPA are a set of economic accounts that provide detailed measures of the value and composition of national output and the incomes generated in the production of that output. Essentially, NIPA provide a detailed snapshot of the myriad transactions that make up the economy—buying and selling goods and services, hiring of labor, investing, renting property, paying taxes, and the like. NIPA estimates show U.S. production, distribution, consumption, investment, and saving. The best-known NIPA measure is the gross domestic product (GDP), which is defined as the market value of the goods and services produced by labor and property located in the United States. NIPA calculate GDP as the sum of familiar final expenditure components: personal consumption expenditures, private investment, government spending (consumption and investment), and net exports. However, GDP is just one of many economic measures presented in NIPA. Other key NIPA estimates presented in Health, United States include the implicit price deflator for GDP and federal and state and local government expenditures. The conceptual framework of NIPA is illustrated by seven summary accounts: the domestic income and product account, the private enterprise income account, the personal income and outlay account, the government receipts and expenditures account, the foreign transactions current account, the domestic capital account, and the foreign transactions capital account. These summary accounts record a use (or expenditure) in one account for one sector and a corresponding source (or receipt) in an account of another sector or of the same sector. This integrated system provides a comprehensive measure of economic activity in a consistently defined framework without double counting. Coverage. Source data for NIPA domestic estimates cover all 50 states and D.C. The U.S. national income and product statistics were first presented as part of a complete and consistent double-entry accounting system in the summer of 1947. Methodology. NIPA estimates are revised on a quarterly, annual, and quinquennial basis. For GDP and most other NIPA series, a set of three current quarterly estimates is released each year. Quarterly estimates provide the first look at the path of U.S. economic activity. Annual revisions of NIPA are usually carried out each summer. These revisions incorporate source data that are based on more extensive annual surveys, on annual data from other sources, and on later revisions to the monthly and quarterly source data, and they generally cover the three previous calendar years. Comprehensive revisions are carried out at about 5-year intervals and may result in revisions that extend back many years. These estimates incorporate all of the best available source data, such as data from the quinquennial U.S. Economic Census. NIPA measures are built up from a wide range of source data using a variety of estimating methods. To ensure consistency and accuracy, NIPA use various adjustment and estimation techniques to estimate data. Three general types of adjustments are made to the source data that are incorporated into the NIPA estimates. The first consists of adjustments that are needed so that the data conform to appropriate NIPA concepts and definitions. The second type of adjustment involves filling gaps in coverage. The third type of adjustment involves time of recording and valuation. Source data must occasionally be adjusted to account for special circumstances that affect the accuracy of the data. For example, quarterly and monthly NIPA estimates are seasonally adjusted at the detailed-series level when the series demonstrate statistically significant seasonal patterns. Source data may also be used as indicators to extrapolate annual estimates. For more information, see ‘‘An introduction to the National Income and Product Accounts methodology papers: U.S. National Income and Product Accounts,’’ available from: http://www.bea.gov/scb/pdf/ national/nipa/methpap/mpi1_0907.pdf; and ‘‘Concepts and methods of the U.S. National Income and Product Accounts,’’ available from: http://www.bea.gov/national/pdf/chapters1 4.pdf. Issues Affecting Interpretation. NIPA source data and estimates are revised frequently. Data are released at different times, estimates are updated as they become available, new concepts and definitions are incorporated, and source data may change due to improvements in collection and new methodologies. As a result, major estimates such as GDP and its major components undergo frequent revision, and historical data are changed. For more information, see the BEA (NIPA) website at: http:// www.bea.gov/national/an1.htm#2012AnnualRevision. Reference U.S. Bureau of Economic Analysis. A guide to the National Income and Product Accounts of the United States. Washington, DC: BEA; 2006. Available from: http:// www.bea.gov/national/pdf/nipaguid.pdf. For More Information. See the BEA (NIPA) website at: http://www.bea.gov/national/index.htm. National Medical Expenditure Survey (NMES)—See Appendix I, Medical Expenditure Panel Survey (MEPS). 376 Appendix I. Data Sources Health, United States, 2014
National Notifiable Diseases Surveillance System (NNDSS) CDC Overview. The CDC National Notifiable Diseases Surveillance System (NNDSS) is a nationwide collaboration that enables all levels of public health (local, state, territorial, federal, and international) to share health information to monitor, control, and prevent the occurrence and spread of statereportable and nationally notifiable infectious and some noninfectious diseases and conditions. NNDSS is a multifaceted program that includes the surveillance system for collection, analysis, and sharing of health data, resources, and information about policies and standards, at the local, state, and national levels. NNDSS provides weekly provisional and annual finalized information on the occurrence of diseases defined as notifiable by the Council of State and Territorial Epidemiologists (CSTE). Data include incidence of reportable diseases, which are nationally notifiable using uniform surveillance case definitions. Coverage. Notifiable disease reports are received from health departments in the 50 states, five territories, D.C., and New York City. Policies for reporting notifiable disease cases can vary by disease or reporting jurisdiction, depending on case status classification (i.e., confirmed, probable, or suspect). Methodology. CDC, in partnership with CSTE, administers NNDSS. Reportable disease surveillance is conducted by public health practitioners at local, state, and national levels to support disease prevention and control and then data on a subset of reportable conditions which have been designated nationally notifiable are submitted to CDC without personal identifiers. The system also provides annual summaries of the finalized data. CSTE and CDC annually review the status of national infectious disease surveillance and recommend additions or deletions to the list of nationally notifiable diseases, based on the need to respond to emerging priorities. For example, Q fever and tularemia became nationally notifiable in 2000. However, reporting nationally notifiable diseases to CDC is voluntary. Because reporting is currently mandated by law or regulation only at the local and state levels, the list of diseases that are considered reportable varies by state. For example, reporting of cyclosporiasis to CDC is not done by some states in which this disease is not reportable to local or state authorities. State epidemiologists report cases of nationally notifiable diseases to CDC, which tabulates and publishes these data in Morbidity and Mortality Weekly Report (MMWR) and in Summary of Notifiable Diseases, United States (before 1985, titled Annual Summary). Issues Affecting Interpretation. NNDSS data must be interpreted in light of reporting practices. Some diseases that cause severe clinical illness (for example, plague and rabies) are likely reported accurately if diagnosed by a clinician. However, persons who have diseases that are clinically mild and infrequently associated with serious consequences (e.g., salmonellosis) may not seek medical care from a health care provider. Even if these less severe diseases are diagnosed, they are less likely to be reported. The degree of completeness of data reporting is also influenced by the diagnostic facilities available, the control measures in effect, public awareness of a specific disease, and the interests, resources, and priorities of state and local officials responsible for disease control and public health surveillance. Finally, factors such as changes in case definitions for public health surveillance, introduction of new diagnostic tests, or discovery of new disease entities can cause changes in disease reporting that are independent of the true incidence of disease. Reference CDC. Summary of notifiable diseases—United States, 2012. MMWR 2014;61(53):1–121. Available from http://www.cdc.gov/mmwr/mmwr_nd/index.html. For More Information. See the NNDSS website at: http://wwwn.cdc.gov/nndss/. National Survey of Family Growth (NSFG) CDC/NCHS Overview. NSFG gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men's and women's health. NSFG provides national data on factors affecting birth and pregnancy rates, adoption, and maternal and infant health. Data collected include sexual activity, marriage, divorce and remarriage, unmarried cohabitation, forced sexual intercourse, contraception and sterilization, infertility, breastfeeding, pregnancy loss, low birthweight, and use of medical care for family planning and infertility. Coverage. NSFG in 1982, 1988, and 1995 included women aged 15–44 in the civilian noninstitutionalized population of the U.S. The 2002, 2006–2010, and 2011–2013 NSFG included both men and women aged 15–44 in the household population of the United States. The household population of the United States refers to the civilian noninstitutionalized population and active-duty military personnel who are not living on military bases. Methodology. The 2006–2010 and 2011–2013 NSFG sample design consisted of five stages of selection: primary sampling units (PSUs), blocks or segments, housing units, one eligible person per housing unit, and housing units or persons for phase 2 data collection (intended to raise response rates and correct any bias due to nonresponse). Samples of 110 PSUs were drawn for 2006–2010 and 117 PSUs were drawn for 2011–2015. Both PSU samples were divided into four fully representative national samples. Interviewing was done for 1 year in each subsample; the Health, United States, 2014 Appendix I. Data Sources 377
Page 2:
Copyright information Permission ha
Page 5 and 6:
Preface Health, United States, 2014
Page 7 and 8:
Accessing Health, United States Hea
Page 9 and 10:
Contents
Page 11 and 12:
Trend Tables Health Status and Dete
Page 13 and 14:
Figure 28. Prescription drug use in
Page 15 and 16:
List of Trend Tables Health Status
Page 17 and 18:
Table 64. Healthy weight, overweigh
Page 19 and 20:
State Health Expenditures and Healt
Page 21 and 22:
Health, United States, 2014: At a G
Page 23 and 24:
Highlights This section presents se
Page 25 and 26:
Use of Preventive Medical Care Serv
Page 27 and 28:
Chartbook: Figures 1-19
Page 29 and 30:
Mortality Selected Causes of Death
Page 31 and 32:
Disability Measures Basic Actions D
Page 33 and 34:
Health Risk Factors Overweight and
Page 35 and 36:
Health Insurance Coverage Among Adu
Page 37 and 38:
Personal Health Care Expenditures M
Page 39 and 40:
Special Feature on Adults Aged 55-6
Page 41 and 42:
Health, United States, 2014: Profil
Page 43 and 44:
Selected Chronic Conditions For adu
Page 45 and 46:
Current Cigarette Smoking In 2012-2
Page 47 and 48:
Health Insurance Coverage For adult
Page 49 and 50:
Use of Preventive Services and Scre
Page 51 and 52:
Delay or Nonreceipt of Medical Care
Page 53 and 54:
Data table for Figure 20. Death rat
Page 55 and 56:
Data table for Figure 22. Serious o
Page 57 and 58:
Data table for Figure 24. Participa
Page 59 and 60:
Data table for Figure 26. Health ca
Page 61 and 62:
Data table for Figure 28. Prescript
Page 63 and 64:
Technical Notes Data Sources and Co
Page 65 and 66:
26. Martinez ME, Cohen RA. Health i
Page 67 and 68:
83. CDC. Vaccine recommendations of
Page 69 and 70:
Table 1 (page 1 of 3). Resident pop
Page 71 and 72:
Table 1 (page 3 of 3). Resident pop
Page 73 and 74:
Table 2 (page 2 of 2). Persons belo
Page 75 and 76:
Table 3 (page 2 of 3). Crude birth
Page 77 and 78:
Table 4 (page 1 of 2). Teenage chil
Page 79 and 80:
Table 5. Nonmarital childbearing, b
Page 81 and 82:
Table 7 (page 1 of 3). Low birthwei
Page 83 and 84:
Table 7 (page 3 of 3). Low birthwei
Page 85 and 86:
Table 9 (page 1 of 6). Contraceptiv
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Table 10. Breastfeeding among mothe
Page 93 and 94:
Table 11 (page 2 of 2). Infant, neo
Page 95 and 96:
Table 13 (page 1 of 3). Infant mort
Page 97 and 98:
Table 13 (page 3 of 3). Infant mort
Page 99 and 100:
Table 15 (page 1 of 2). Life expect
Page 101 and 102:
Table 16 (page 1 of 2). Life expect
Page 103 and 104:
Table 17 (page 1 of 2). Age-adjuste
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Table 19 (page 1 of 4). Years of po
Page 111 and 112:
Table 19 (page 3 of 4). Years of po
Page 113 and 114:
Table 20 (page 1 of 4). Leading cau
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Table 23 (page 2 of 4). Death rates
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Table 36 (page 1 of 2). Occupationa
Page 163 and 164:
Table 37 (page 1 of 2). Selected no
Page 165 and 166:
Table 38 (page 1 of 2). Human immun
Page 167 and 168:
Table 39 (page 1 of 5). Health cond
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Table 42 (page 1 of 2). Respondent-
Page 179 and 180:
Table 43 (page 1 of 2). Number of r
Page 181 and 182:
Table 44 (page 1 of 2). Diabetes pr
Page 183 and 184:
Table 45 (page 1 of 2). End-stage r
Page 185 and 186:
Table 46 (page 1 of 3). Severe head
Page 187 and 188:
Table 46 (page 3 of 3). Severe head
Page 189 and 190:
Table 47 (page 2 of 2). Disability
Page 191 and 192:
Table 48 (page 2 of 2). Vision limi
Page 193 and 194:
Table 49 (page 2 of 2). Hearing lim
Page 195 and 196:
Table 50 (page 2 of 2). Respondent-
Page 197 and 198:
Table 51 (page 2 of 2). Serious psy
Page 199 and 200:
Table 52 (page 2 of 2). Current cig
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Table 55 (page 2 of 2). Use of sele
Page 207 and 208:
Table 56 (page 2 of 3). Use of sele
Page 209 and 210:
Table 57 (page 1 of 3). Health risk
Page 211 and 212:
Table 57 (page 3 of 3). Health risk
Page 213 and 214:
Table 58 (page 2 of 3). Heavier dri
Page 215 and 216:
Table 59 (page 1 of 2). Selected he
Page 217 and 218:
Table 60 (page 1 of 2). Hypertensio
Page 219 and 220:
Table 61 (page 1 of 4). Cholesterol
Page 221 and 222:
Table 61 (page 3 of 4). Cholesterol
Page 223 and 224:
Table 62 (page 1 of 2). Mean macron
Page 225 and 226:
Table 63 (page 1 of 5). Participati
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Table 64 (page 2 of 7). Healthy wei
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Table 65 (page 1 of 2). Obesity amo
Page 239 and 240:
Table 66 (page 1 of 2). Untreated d
Page 241 and 242:
Table 67 (page 1 of 2). No usual so
Page 243 and 244:
Table 68 (page 1 of 2). No usual so
Page 245 and 246:
Table 69 (page 1 of 3). Delay or no
Page 247 and 248:
Table 69 (page 3 of 3). Delay or no
Page 249 and 250:
Table 70 (page 2 of 2). No health c
Page 251 and 252:
Table 71 (page 2 of 3). Health care
Page 253 and 254:
Table 72 (page 1 of 3). Vaccination
Page 255 and 256:
Table 72 (page 3 of 3). Vaccination
Page 257 and 258:
Table 74 (page 1 of 2). Influenza v
Page 259 and 260:
Table 75 (page 1 of 2). Pneumococca
Page 261 and 262:
Table 76 (page 1 of 3) . Use of mam
Page 263 and 264:
Table 76 (page 3 of 3). Use of mamm
Page 265 and 266:
Table 77 (page 2 of 5). Use of Pap
Page 267 and 268:
Table 77 (page 4 of 5). Use of Pap
Page 269 and 270:
Table 78 (page 1 of 2). Use of colo
Page 271 and 272:
Table 79 (page 1 of 4). Emergency d
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Table 81 (page 2 of 2). Initial inj
Page 281 and 282:
Table 82 (page 2 of 3). Visits to p
Page 283 and 284:
Table 83 (page 1 of 2). Visits to p
Page 285 and 286:
Table 84 (page 1 of 2) . Dental vis
Page 287 and 288:
Table 85 (page 1 of 2). Prescriptio
Page 289 and 290:
Table 86 (page 1 of 3). Selected pr
Page 291 and 292:
Table 86 (page 3 of 3). Selected pr
Page 293 and 294:
Table 87 (page 2 of 4). Persons wit
Page 295 and 296:
Table 87 (page 4 of 4). Persons wit
Page 297 and 298:
Table 88 (page 2 of 3). Discharges,
Page 299 and 300:
Table 89 (page 1 of 3). Discharge r
Page 301 and 302:
Table 89 (page 3 of 3). Discharge r
Page 303 and 304:
Table 90 (page 2 of 4). Discharges
Page 305 and 306:
Table 90 (page 4 of 4). Discharges
Page 307 and 308:
Table 92. Active physicians and phy
Page 309 and 310:
Table 94. Doctors of medicine in pr
Page 311 and 312:
Table 96. Healthcare employment and
Page 313 and 314:
Table 98. Hospitals, beds, and occu
Page 315 and 316:
Table 100. Occupancy rates in commu
Page 317 and 318:
Table 101 (page 2 of 2). Nursing ho
Page 319 and 320:
Table 102 (page 2 of 2). Gross dome
Page 321 and 322:
Table 103 (page 2 of 2). National h
Page 323 and 324:
Table 104 (page 2 of 3). Personal h
Page 325 and 326:
Table 105 (page 1 of 3). Cost of ho
Page 327 and 328:
Table 105 (page 3 of 3). Cost of ho
Page 329 and 330:
Table 106 (page 2 of 3). Expenses f
Page 331 and 332:
Table 107 (page 1 of 3). Sources of
Page 333 and 334:
Table 107 (page 3 of 3). Sources of
Page 335 and 336:
Table 109 (page 1 of 2). National h
Page 337 and 338:
Table 110. Employers' costs per emp
Page 339 and 340: Table 111 (page 2 of 3). Private he
Page 345 and 346: Table 113 (page 2 of 3). Medicaid c
Page 347 and 348: Table 114 (page 1 of 3). No health
Page 349 and 350: Table 114 (page 3 of 3). No health
Page 351 and 352: Table 115 (page 2 of 2). Health ins
Page 353 and 354: Table 116 (page 2 of 2). Medicare e
Page 355 and 356: Table 117 (page 2 of 2). Medicare b
Page 357 and 358: Table 118 (page 2 of 2). Medicaid b
Page 359 and 360: Table 120. Department of Veterans A
Page 361 and 362: Table 121 (page 2 of 2). Medicare e
Page 363 and 364: Table 123 (page 1 of 3). Persons un
Page 365 and 366: Table 123 (page 3 of 3). Persons un
Page 367 and 368: Appendix Contents Appendix I. Data
Page 369 and 370: Mammography .......................
Page 371 and 372: Appendix I. Data Sources Health, Un
Page 373 and 374: institutional group quarters popula
Page 375 and 376: entire survey. In addition, some of
Page 377 and 378: Another source of Medicaid informat
Page 379 and 380: For More Information. See the CMS R
Page 381 and 382: Sample data are weighted to produce
Page 383 and 384: The estimation procedure used to pr
Page 385 and 386: with the Armed Forces (although the
Page 387 and 388: areas. EDs are treated as their own
Page 389: Methodology. NIS is a nationwide te
Page 393 and 394: interviewing (ACASI), are used to p
Page 395 and 396: Coverage. Data presented in Health,
Page 397 and 398: Heron M, Hoyert DL, Murphy SL, et a
Page 399 and 400: specified rules for the collection,
Page 401 and 402: Quality Improvement Evaluation Syst
Page 403 and 404: information on treatment and payer
Page 405 and 406: Reference American Dental Associati
Page 407 and 408: For More Information. See The Guttm
Page 409 and 410: Table I. United States projected ye
Page 411 and 412: males and black females in 1950 are
Page 413 and 414: hypertension. Those with uncontroll
Page 415 and 416: Table IV. Cause-of-death codes, by
Page 417 and 418: High Blood Cholesterol in Adults (A
Page 419 and 420: Table V. Comparability of selected
Page 421 and 422: Dental caries was identified by an
Page 423 and 424: For more information on prescriptio
Page 425 and 426: public-use data release. NCHS. 2014
Page 427 and 428: Figure I. U.S. Census Bureau: Four
Page 429 and 430: with only Indian Health Service (IH
Page 431 and 432: Table VII. Percentage of persons un
Page 433 and 434: analytic purposes. See: NAACCR guid
Page 435 and 436: cause of death in ICD-9. The asteri
Page 437 and 438: Table IX. Codes for external causes
Page 439 and 440: U.S. life tables by Hispanic origin
Page 441 and 442:
for Healthcare Research and Quality
Page 443 and 444:
Affordable Care Act Provides Eligib
Page 445 and 446:
Micropolitan statistical area—The
Page 447 and 448:
In 2000 and 2003, women were asked
Page 449 and 450:
see Appendix I, Population Census a
Page 451 and 452:
Table XII. Codes for procedure cate
Page 453 and 454:
Table XIV. Private health care cove
Page 455 and 456:
the extent that race and Hispanic o
Page 457 and 458:
Perinatal mortality rates and ratio
Page 459 and 460:
coverage are considered uninsured.
Page 461 and 462:
Index
Page 463 and 464:
A—Con. Table/Figure (F) Asian or
Page 465 and 466:
D Table/Figure (F) Deaths, death ra
Page 467 and 468:
H—Con. Table/Figure (F) Hispanic
Page 469 and 470:
M—Con. Table/Figure (F) Metropoli
Page 471 and 472:
S Table/Figure (F) Salmonellosis, s
show all

hus14

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?